Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2016

Open Access 01-12-2016 | Research article

Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study

Authors: Johannes Nossent, Warren Raymond, Mark Divitini, Matthew Knuiman

Published in: BMC Cardiovascular Disorders | Issue 1/2016

Login to get access

Abstract

Background

To investigate the impact of uric acid (UA) levels on cardiovascular disease and mortality at a population level.

Methods

Prospective analysis of baseline serum UA measurement and 15 year follow-up data from the Busselton Health Survey (n = 4,173), stratified by existence or absence of baseline cardiovascular disease. Outcomes were ascertained from state-wide hospital discharge and mortality registries. Cox regression produced adjusted hazard ratios (HR) for UA level as continuous and categorical (low, medium, high) predictor for cardiovascular events (CVE) and mortality. Gout was defined as a patient’s self-reported history of gout.

Results

After age and gender adjustment each 0.1 mmol/L rise in UA level was associated with increased mortality (HR 1.19, CI 1.04–1.36), cardiovascular mortality (HR 1.27, CI 1.03–1.57) and first CVE (HR 1.28, CI 1.13–1.44) in participants with no history of CVE. Adjustment for behavioural and biomedical risk factors of cardiovascular disease attenuated these associations. Results for participants with a history of CVE and for a subset of 1,632 participants using UA levels (2–6 measurements) averaged over time were similar. The overall prevalence of hyperuricemia was 10.7%. When stratified by history of gout, UA level was significantly associated with increased risk of cardiovascular mortality only in participants with a history of CVE (HR 2.13, CI 1.03–4.43).

Conclusions

Despite the considerable prevalence of hyperuricemia in 10.7% of the population, single or time averaged measures of UA were not independently predictive of incident cardiovascular disease or mortality. Hyperuricemia did associate with an increased risk of cardiovascular death only in participants with gout and existing cardiovascular disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Watanabe S, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40(3):355–60.CrossRefPubMed Watanabe S, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40(3):355–60.CrossRefPubMed
2.
go back to reference Baroja-Mazo A, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014;15(8):738–48.CrossRefPubMed Baroja-Mazo A, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014;15(8):738–48.CrossRefPubMed
3.
go back to reference Bunim JJ, McEwen C. Tophus of mitral valve in gout. Arch Pathol. 1940;29:700–4. Bunim JJ, McEwen C. Tophus of mitral valve in gout. Arch Pathol. 1940;29:700–4.
5.
go back to reference Ginsberg MH, Kozin F. Mechanisms of cellular interaction with monosodium urate crystals. IgG-dependent and IgG-independent platelet stimulation by urate crystals. Arthritis Rheum. 1978;21(8):896–903.CrossRefPubMed Ginsberg MH, Kozin F. Mechanisms of cellular interaction with monosodium urate crystals. IgG-dependent and IgG-independent platelet stimulation by urate crystals. Arthritis Rheum. 1978;21(8):896–903.CrossRefPubMed
7.
go back to reference Kanbay M, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99:759–66.CrossRefPubMed Kanbay M, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99:759–66.CrossRefPubMed
8.
9.
go back to reference Kim SY, et al. Hyperuricemia and risk of stroke: A systematic review and meta‐analysis. Arthritis Care Res. 2009;61(7):885–92.CrossRef Kim SY, et al. Hyperuricemia and risk of stroke: A systematic review and meta‐analysis. Arthritis Care Res. 2009;61(7):885–92.CrossRef
10.
go back to reference Simons L, Jones A. Coronary risk factor screening and long-term follow up: year 1 of the Sydney Coronary Heart Disease Prevention Programme. Med J Aust. 1978;2(10):455–8.PubMed Simons L, Jones A. Coronary risk factor screening and long-term follow up: year 1 of the Sydney Coronary Heart Disease Prevention Programme. Med J Aust. 1978;2(10):455–8.PubMed
11.
go back to reference Juraschek SP, et al. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. PLoS One. 2013;8(2):e56546.CrossRefPubMedPubMedCentral Juraschek SP, et al. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. PLoS One. 2013;8(2):e56546.CrossRefPubMedPubMedCentral
12.
go back to reference Robinson PC, Taylor WJ, Dalbeth N. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. J Rheumatol. 2015;42:1702–7.CrossRefPubMed Robinson PC, Taylor WJ, Dalbeth N. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. J Rheumatol. 2015;42:1702–7.CrossRefPubMed
13.
go back to reference van Durme C, et al. Cardiovascular Risk Factors and Comorbidities in Patients with Hyperuricemia and/or Gout: A Systematic Review of the Literature. J Rheumatol. 2014;92:9–14. van Durme C, et al. Cardiovascular Risk Factors and Comorbidities in Patients with Hyperuricemia and/or Gout: A Systematic Review of the Literature. J Rheumatol. 2014;92:9–14.
14.
go back to reference Bos MJ, et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37(6):1503–7.CrossRefPubMed Bos MJ, et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37(6):1503–7.CrossRefPubMed
15.
go back to reference Chang HY, et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci. 2010;339(6):509–15.CrossRefPubMed Chang HY, et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci. 2010;339(6):509–15.CrossRefPubMed
16.
go back to reference Gonzalez A, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67(1):64–9.CrossRefPubMed Gonzalez A, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67(1):64–9.CrossRefPubMed
17.
go back to reference Grayson PC, et al. Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care Res. 2011;63(1):102–10.CrossRef Grayson PC, et al. Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care Res. 2011;63(1):102–10.CrossRef
18.
go back to reference Huang H, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16(1):15–24.CrossRefPubMed Huang H, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16(1):15–24.CrossRefPubMed
19.
go back to reference Kim SY, et al. Hyperuricemia and Coronary Heart Disease: A Systematic Review and Meta-Analysis. Arthritis care res. 2010;62(2):170–80. Kim SY, et al. Hyperuricemia and Coronary Heart Disease: A Systematic Review and Meta-Analysis. Arthritis care res. 2010;62(2):170–80.
20.
go back to reference Kuo D, et al. Hyperuricemia and Incident Cardiovascular Disease and Noncardiac Vascular Events in Patients with Rheumatoid Arthritis. International Journal of Rheumatology. 2014;2014:7.CrossRef Kuo D, et al. Hyperuricemia and Incident Cardiovascular Disease and Noncardiac Vascular Events in Patients with Rheumatoid Arthritis. International Journal of Rheumatology. 2014;2014:7.CrossRef
21.
go back to reference Clarson L, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2013;22:335–43.CrossRefPubMed Clarson L, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2013;22:335–43.CrossRefPubMed
22.
go back to reference Lottmann K, Chen X, Schadlich PK. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep. 2012;14(2):195–203.CrossRefPubMedPubMedCentral Lottmann K, Chen X, Schadlich PK. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep. 2012;14(2):195–203.CrossRefPubMedPubMedCentral
24.
go back to reference Johnson RJ, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183–90.CrossRefPubMed Johnson RJ, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183–90.CrossRefPubMed
25.
go back to reference Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139(9):761–76.CrossRefPubMed Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139(9):761–76.CrossRefPubMed
26.
go back to reference Hickling S, et al. Are the associations between diet and C-reactive protein independent of obesity? Prev Med. 2008;47(1):71–6.CrossRefPubMed Hickling S, et al. Are the associations between diet and C-reactive protein independent of obesity? Prev Med. 2008;47(1):71–6.CrossRefPubMed
27.
go back to reference Knuiman MW, et al. Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study. Eur J Cardiovasc Prev Rehabil. 2009;16(2):235–41.CrossRefPubMed Knuiman MW, et al. Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study. Eur J Cardiovasc Prev Rehabil. 2009;16(2):235–41.CrossRefPubMed
28.
go back to reference Kelman CW, Bass AJ, Holman CDJ. Research use of linked health data — a best practice protocol. Aust N Z J Public Health. 2002;26(3):251–5.CrossRefPubMed Kelman CW, Bass AJ, Holman CDJ. Research use of linked health data — a best practice protocol. Aust N Z J Public Health. 2002;26(3):251–5.CrossRefPubMed
29.
go back to reference Culleton BF, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7–13.CrossRefPubMed Culleton BF, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7–13.CrossRefPubMed
30.
go back to reference Panero F, et al. Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study. Atherosclerosis. 2012;221(1):183–8.CrossRefPubMed Panero F, et al. Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study. Atherosclerosis. 2012;221(1):183–8.CrossRefPubMed
32.
go back to reference Sundstrom J, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45(1):28–33.CrossRefPubMed Sundstrom J, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45(1):28–33.CrossRefPubMed
33.
go back to reference Kawamoto R, et al. Usefulness of combining serum uric acid and high-sensitivity C-reactive protein for risk stratification of patients with metabolic syndrome in community-dwelling women. Endocrine. 2013;44(1):132–9.CrossRefPubMedPubMedCentral Kawamoto R, et al. Usefulness of combining serum uric acid and high-sensitivity C-reactive protein for risk stratification of patients with metabolic syndrome in community-dwelling women. Endocrine. 2013;44(1):132–9.CrossRefPubMedPubMedCentral
34.
go back to reference Kang DH, et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553–62.CrossRefPubMed Kang DH, et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553–62.CrossRefPubMed
35.
36.
go back to reference Feig DI, et al. Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol. 2006;17(4 Suppl 2):S69–73.CrossRefPubMed Feig DI, et al. Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol. 2006;17(4 Suppl 2):S69–73.CrossRefPubMed
37.
39.
go back to reference Zhang Q, et al. A longitudinal cohort based association study between uric acid level and metabolic syndrome in Chinese Han urban male population. BMC Public Health. 2012;12:419.CrossRefPubMedPubMedCentral Zhang Q, et al. A longitudinal cohort based association study between uric acid level and metabolic syndrome in Chinese Han urban male population. BMC Public Health. 2012;12:419.CrossRefPubMedPubMedCentral
40.
go back to reference Storhaug HM, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromso Study. BMC Cardiovasc Disord. 2013;13:115.CrossRefPubMedPubMedCentral Storhaug HM, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromso Study. BMC Cardiovasc Disord. 2013;13:115.CrossRefPubMedPubMedCentral
41.
go back to reference Abbott RD, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41(3):237–42.CrossRefPubMed Abbott RD, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41(3):237–42.CrossRefPubMed
42.
go back to reference Annemans L, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67(7):960–6.CrossRefPubMed Annemans L, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67(7):960–6.CrossRefPubMed
43.
go back to reference Robinson PC, et al. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999–2009. Rheumatology (Oxford). 2013;52(1):118–26.CrossRef Robinson PC, et al. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999–2009. Rheumatology (Oxford). 2013;52(1):118–26.CrossRef
44.
go back to reference Choi HK, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109–15.CrossRefPubMed Choi HK, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109–15.CrossRefPubMed
45.
go back to reference Perez-Ruiz F, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177–82.CrossRefPubMed Perez-Ruiz F, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177–82.CrossRefPubMed
46.
go back to reference Dalbeth N, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann Rheum Dis. 2015;74(5):908–11.CrossRefPubMed Dalbeth N, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann Rheum Dis. 2015;74(5):908–11.CrossRefPubMed
47.
go back to reference Trifiro G, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis. 2013;72(5):694–700.CrossRefPubMed Trifiro G, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis. 2013;72(5):694–700.CrossRefPubMed
49.
go back to reference Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2):186–91.CrossRefPubMed Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2):186–91.CrossRefPubMed
51.
52.
go back to reference Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41.CrossRefPubMed Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41.CrossRefPubMed
53.
go back to reference Ting K, et al. Prevalence and Associations of Gout and Hyperuricaemia: Results from an Australian Population-based Study. Intern Med J. 2016;46:566–73.CrossRefPubMed Ting K, et al. Prevalence and Associations of Gout and Hyperuricaemia: Results from an Australian Population-based Study. Intern Med J. 2016;46:566–73.CrossRefPubMed
54.
go back to reference Robinson PC, et al. Insight into rheumatological cause and effect through the use of Mendelian randomization. Nat Rev Rheumatol. 2016;12(8):486–96.CrossRefPubMed Robinson PC, et al. Insight into rheumatological cause and effect through the use of Mendelian randomization. Nat Rev Rheumatol. 2016;12(8):486–96.CrossRefPubMed
Metadata
Title
Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study
Authors
Johannes Nossent
Warren Raymond
Mark Divitini
Matthew Knuiman
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2016
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-016-0421-1

Other articles of this Issue 1/2016

BMC Cardiovascular Disorders 1/2016 Go to the issue